The botox in dentistry, a review study

W. Salém, Alanood Alshammari, Fatimah Alshehri
{"title":"The botox in dentistry, a review study","authors":"W. Salém, Alanood Alshammari, Fatimah Alshehri","doi":"10.15406/MOJI.2018.06.00229","DOIUrl":null,"url":null,"abstract":"The Botulinum toxin can be considered as a neurotoxin present in nature. It is produced by the Clostridium botulinum Bacteria. Botox is the most commonly known commercial name for the Botulinum toxin.1 It is a strong toxin because as little as 30–100 mg can be theoretically fatal. Ingesting of a few milligrams of such toxin in contaminated food can cause severe illness or even death to humans, animals, and birds.2 Once the toxin reaches the cytoplasm of the nerve cells, the toxin prevents the release of acetylcholine. This stops the nerve signal and paralysis may occur. By the 2002, the FDA accepted the Allergan’s Botox cosmetic for the resolution of momentarily deleting the facial lines. For several years, many physicians also have used Botox “off-label” (without FDA approval) in treating some other medical problems.3 Those injections obviously diminish those seriousness of motor contraction–induced abnormal head position and accompanying with neck pain. Also in 2000, the FDA accepted BoNT/B as a treatment for cervical dystonia in the patients who developed BoNT/A resistance. Since that time, BoNT/A has been accepted for the decrease of the deep glabellar lines in the face. FDA accepted the use of specifications for BoNT/A and BoNT/B. 4 Nowadays, many dentists worldwide are providing the botulinum toxin (Botox) to their patients. The following is a review of the scientific literature about benefit of Botox in Dentistry problems.5","PeriodicalId":90928,"journal":{"name":"MOJ immunology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MOJ immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15406/MOJI.2018.06.00229","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

The Botulinum toxin can be considered as a neurotoxin present in nature. It is produced by the Clostridium botulinum Bacteria. Botox is the most commonly known commercial name for the Botulinum toxin.1 It is a strong toxin because as little as 30–100 mg can be theoretically fatal. Ingesting of a few milligrams of such toxin in contaminated food can cause severe illness or even death to humans, animals, and birds.2 Once the toxin reaches the cytoplasm of the nerve cells, the toxin prevents the release of acetylcholine. This stops the nerve signal and paralysis may occur. By the 2002, the FDA accepted the Allergan’s Botox cosmetic for the resolution of momentarily deleting the facial lines. For several years, many physicians also have used Botox “off-label” (without FDA approval) in treating some other medical problems.3 Those injections obviously diminish those seriousness of motor contraction–induced abnormal head position and accompanying with neck pain. Also in 2000, the FDA accepted BoNT/B as a treatment for cervical dystonia in the patients who developed BoNT/A resistance. Since that time, BoNT/A has been accepted for the decrease of the deep glabellar lines in the face. FDA accepted the use of specifications for BoNT/A and BoNT/B. 4 Nowadays, many dentists worldwide are providing the botulinum toxin (Botox) to their patients. The following is a review of the scientific literature about benefit of Botox in Dentistry problems.5
牙科中的肉毒杆菌毒素,一项综述研究
肉毒杆菌毒素可以被认为是一种存在于自然界中的神经毒素。它是由肉毒杆菌产生的。肉毒杆菌毒素是肉毒杆菌毒素最常见的商业名称。1它是一种强毒素,因为理论上只要30–100毫克就可以致命。在受污染的食物中摄入几毫克这种毒素会导致人类、动物和鸟类患上严重疾病,甚至死亡。2一旦毒素到达神经细胞的细胞质,毒素就会阻止乙酰胆碱的释放。这会停止神经信号,并可能发生瘫痪。到2002年,美国食品药品监督管理局接受了Allergan的肉毒杆菌毒素化妆品,以解决暂时删除面部线条的问题。几年来,许多医生还使用肉毒杆菌毒素“标示外”(未经美国食品药品监督管理局批准)治疗其他一些医疗问题。3这些注射明显减轻了运动收缩的严重性,运动收缩导致头部位置异常并伴有颈部疼痛。同样在2000年,美国食品药品监督管理局接受了BoNT/B作为治疗BoNT/a耐药性患者的子宫颈肌张力障碍的药物。从那时起,BoNT/A已经被接受用于减少面部深层眉间纹。美国食品药品监督管理局接受使用BoNT/A和BoNT/B的规范。4如今,世界各地的许多牙医都在为患者提供肉毒杆菌毒素。以下是关于肉毒杆菌毒素在牙科问题中的益处的科学文献综述。5
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信